Organization type
- Pharma
Early phases
- Target identification – new biological hypothesis
- Target validation – Hypothesis verification
Screening
-
Assay development
- In vitro screening models
- In vivo screening models
-
Chemical libraries
- Small molecules (including natural product, DNA encoded libraries and fragment libraries)
-
Fragment based screening
- Hit expansion. Medicinal chemistry programs.
- Virtual screening
- Screening and high throughput screening using small molecules (including natural product, DNA encoded libraries and fragment libraries)
Optimization phases
- In vitro biochemical models(including assay/model development and testing)
- In vitro cellular and organotypic 3D models (including assay/model development and testing)
- In vivo animal models (including assay/model development and testing)
- Medicinal chemistry programs for hit to lead and lead optimization
-
Preclinical phase (including assay/model development and testing)(non-regulatory and regulatory)
- ADME / DMPK
Functional areas
- Compound management
-
Molecular and cellular biology
- Cell line generation
- Flow cytometry
- Gene editing
- qPCR
Terapeutic areas
- Dermatology